Standardized phytochemical actives, certified screening assays, and preclinical regulatory pipelines tailored to international pharmacopeia compliance.
GCP-compliant clinical study design, protocol formulation, small-cohort efficacy verification, and multicenter human trials for NDA registration.
Targeted bioassays, enzyme inhibition kinetics, cellular uptake profiling, and phenotypic screening on validated mammalian cell models.
HPTLC, HPLC-MS/MS, GC-FID, and chromatographic fingerprinting methodologies verified under rigorous ICH Q2(R1) guidelines.
Multivariate potency evaluations analyzing geographic origin (Daodi markers), harvesting seasonality, and specific anatomical botanical fractions.
Rodent toxicology, acute oral LD50 determination, 90-day subchronic evaluations, and in vivo pharmacokinetics for botanical new drug dossiers.
Bioactivity-directed fractionation isolating polyphenols, triterpenoids, polysaccharides, and secondary alkaloids from terrestrial herbs.
Industrial-scale supercritical CO2, macroporous resin adsorption, countercurrent chromatography, and high-vacuum crystallization platforms.
Micro-encapsulation, spray freeze-drying, nano-emulsification, and solid-dosage tableting minimizing active constituent degradation.
Addressing regulatory harmonization, botanical traceability, and technological scalability across global therapeutic markets.
Traditional plant procurement is fraught with chemical variance driven by microclimatic fluctuations, seasonal harvesting variations, and inaccurate botanical authentication. MedGence leverages rigorous genomic barcoding alongside chromatographic fingerprinting to secure traceable raw material pipelines that meet strict therapeutic specs across commercial production cycles.
Exporting natural medicines across FDA (NDI/GRAS), EMA (Traditional Herbal Medicinal Products Directive), and NMPA boundaries requires harmonized quality dossiers. We establish analytical frameworks directly aligned with international pharmacopeial monographs (USP, Ph. Eur., ChP) eliminating multi-regional submission failures and redundant testing cycles.
A recurring failure mode in phytochemistry is the translation gap between bench-scale solvent extractions and industrial CDMO batch yield. Our in-house pilot production infrastructure verifies thermolabile degradation dynamics, mass balances, and crystallization recovery rates prior to full commercial batch validation.
Fourteen years of verifiable contract research execution across mainland China's leading pharmaceutical hubs and hospital networks.
A zero-compromise quality infrastructure engineered to safeguard formulations, enforce Good Agricultural and Collection Practices (GACP), and support commercial filing.
Our laboratories execute batch-specific testing protocols covering over 500 pesticide residues via GC-MS/MS and LC-MS/MS, heavy metals (Lead, Arsenic, Cadmium, Mercury via ICP-MS), aflatoxins (B1, B2, G1, G2), and microbial limits according to USP <561> and EP 2.8.13 guidelines.
Contracting research under an entrusted model demands institutional confidentiality. We utilize physically segmented clean-room environments, restricted server data permissions, and formal legally binding NDA constructs, safeguarding extraction protocols, yields, and formulation ratios.
Eliminate technology hand-off friction. Our Changsha analytical team manages the pilot extraction plant and directly oversees our collaborative cGMP manufacturing facilities, preventing yield degradation and analytical standard drop-offs during commercial scale-up.
Tailoring botanical chemistry, bio-absorption bioavailability, and organoleptic properties to specific regulatory sectors.
Providing bio-available, water-dispersible botanical powders, spray-dried standardized extracts, and granular systems. Optimized for stability across shelf-life, taste-masking of bitter phytochemical fractions, and high active-potency density.
Supporting IND/NDA regulatory submissions through GLP animal toxicology, LD50 profiling, Phase I to IV human clinical evaluation, and strict multi-marker fingerprint quantification across active raw materials and finished dosage capsules.
Solvent-free, clean-label plant fractionations targeting anti-inflammatory, tyrosinase inhibition, and barrier-repair pathways. Backed by certified cell-line safety screening, skin patch sensitization testing, and organotypic skin models.
Direct collaboration across research, quality registration, clinical verification, and contract manufacturing.
Integrating computational molecular docking, synthetic biology, and automated green extraction technologies.
Deploying deep-learning computational chemistry to screen tens of thousands of natural compounds against established cancer, metabolic, and neurological protein receptor structures, compressing discovery cycles from years to months.
Transitioning commercial CDMO lines toward continuous countercurrent supercritical extractions and pulsed electric field technologies, reducing solvent energy burdens by 45% while preserving thermo-sensitive bioactive components.
Utilizing recombinant biocatalysts for selective glycosylation of natural ginsenosides and flavonoids, overcoming hydrophobic limitations and achieving superior human enterocyte absorption profiles.
Integrating decentralized ledger tracking from wild-crafted cultivation fields to finished commercial pallets, giving global brand buyers immutable audit trails for GAP, pesticide clearance, and chemical potency.
Crucial regulatory, analytical, and supply chain insights for evaluating a China-based natural medicine CRO & CDMO partner.
Select a specialized contract study module or commercial production package to advance your botanical lifecycle pipeline.
Human pharmacokinetics, double-blind placebo control trials, and therapeutic endpoint verifications for dietary supplements and botanical new drug dossiers.
High-throughput enzymatic screening, cell viability testing, free radical scavenging assays, and real-time RT-qPCR biomarker expression mapping.
Validation of chromatography standards, reference marker isolation, limit of quantitation (LOQ) tests, and multi-peak fingerprinting consistency.
Seasonal variation screening, geographic origin tracing, and comparative phytochemical concentration mapping across root, leaf, and seed tissues.
Preclinical animal models establishing toxicokinetics, safe consumption margins, anti-hyperglycemic responses, and systemic safety indices.
Systematic screening of complex plant fractions to pinpoint primary bioactive compounds responsible for metabolic and therapeutic efficacy.
Multi-herb compatibility science, synergy ratios, and modern preparation registrations based on classical pharmacopoeial formulations.
Full-scale OEM/CDMO production for softgels, tablets, oral liquids, and soluble botanical concentrates with complete batch release documentation.
Connect directly with our Changsha scientific leadership team to discuss target indications, screening protocols, or contract manufacturing specifications.
